Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation

Blood

Volumn 89, Issue 6, 1997, Pages 2184-2188

  Salat, Christoph ^a   Holler, Ernst ^b   Kolb, Hans Jochem ^b   Reinhardt, Brigitte ^b   Pihusch, Rudolf ^b   Wilmanns, Wolfgang ^b   Hiller, Erhard ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; APLASTIC ANEMIA; ARTICLE; BIOPSY; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LEUKEMIA; LIVER INJURY; LIVER VEIN OBSTRUCTION; LYMPHOBLASTOMA; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0030933936     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2184     Document Type: Article

References (32)

1. Bras G, Jeliffe DB, Stuart KL: Veno-occlusive disease of the liver with nonportal type of cirrhosis occurring in Jamaica. Arch pathol 57:285, 1954
2. Shulman HM, Gown AM, Nugent DJ: Hepatic veno-occlusive disease after bone marrow transplantation immunohistochemical identification of the material within occluded central venules. Am J Pathol 127:549, 1987
3. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB: Veno-occlusive disease of the liver after marrow transplanta-tion: Histological correlates of clinical signs and symptoms. Hepatology 19:1171, 1994
4. Mc Donald GB, Sharma P, Matthews DE: Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 4:116, 1984
5. Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R: Venooccclusive disease of the liver following bone marrow transplantation. Transplantation 44:778, 1987
6. Bearman SI, Shuhart MC, Hinds MS, Mc Donald GB: Recombinant human tissue plasminogen activator (tPA) for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 80:2458, 1992
7. Eltumi M, Trivedi P, Hobbs JR, Portmann B, Cheeseman P, Downie C, Risteli J, Risteli L, Mowat AP: Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 342:518, 1993
8. Heikinheimo M, Halila R, Fasth A: Serum procollagen type III is an early and sensitive marker for veno-oeclusive disease of the liver in children undergoing bone marrow transplantation. Blood 83:3036, 1994
9. Rio B, Bauduer F, Arrago JP, Zittoun R: N-terminal peptide of type III procollagen: A marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 11:471, 1993
10. Scrobohaci L, Drouet L, Monem-Mansi A, Devergie A. Baudin B, D'Agay MF, Gluckman E: Liver veno-occlusive disease after bone marrow transplantation. Changes in coagulation parameters and endothelial cell markers. Thromb Res 63:509, 1991
11. Faioni EM, Krachmalnikoff A. Bearman SI: Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of veno-occclusive disease of the liver. Blood 81:3458. 1993
12. Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE: Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 5:39, 1990
13. Salat C, Holler E, Kolb HJ, Hiller E: Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 342:1062, 1993 (letter)
14. Salat C, Holler E, Reinhardt B, Kolb HJ, Seeber B, Ledderose G. Mittermueller J, Duell T, Wilmanns W, Hiller E: Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 14:747, 1994
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295, 1974
16. Mc Donald GB, Shulman HM, Wolford JL, Spencer GD: Liver disease after human marrow transplantation. Semin Liver Dis 7:210, 1987
17. Mc Donald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow trans-plantation: A cohort study of 355 patients. Ann Intern Med 118:255, 1993
18. Bearman SI: The syndrome of hepatic veno-acclusive disease after marrow transplantation. Blood 85:3005, 1995
19. Pralong G. Calandra T, Glauser MP, Schellekens J, Vefhoef J, Bachmann F, Kruithof EKO: Plasminogen activator inhibitor 1: A prognostic marker in septic shock. Thromb Haemost 61:459. 1989
20. Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D: Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 65:291. 1991
21. Hesselvik JF; Blombäck M, Brodin B, Maller R: Coagulation, fibrinolyisis, and kallikrein systems in sepsis: Relation to outcome. Crit Care Med 17:724, 1989
22. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536, 1993
23. Voss R, Matthias FR. Borkowski G, Reitz D: Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75:99, 1990
24. Salat C, Boekstegers P, Holler E, Werdan K. Reinhardt B, Fateh-Moghadam S, Pihusch R, Kaul M, Beinert T, Hiller E: Hemostatic parameters in sepsis patients treated with anti-TNFα-monoclonal antibodies. Shock 6:233, 1996
25. Mesters RM, Flörke N, Ostermann H, Kienast J: Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 75:902, 1996
26. Haj AM. Neilly IJ, Robbie LA, Adey GD, Bennett B: Influence of white blood cells on the fibrinolytic response to sepsis: Studies of septic patients with or without severe leukopenia. Br J Haematol 90:541, 1995
27. Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Göhring P, Poley S, Hiller E: Hemostatic parameters in a patient undergoing bone marrow and subsequent liver transplantation due to veno-occlusive disease. Ann Hematol 72:A72, 1996 (abstr, supp 1)
28. Deleve DL: Dacarbazine toxicity in murine liver cells: A model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 268:1261, 1994
29. Van Hinsbergh VW, Kooistra T, Van Den Berg EA, Princen HM, Fiers W, Emeis JJ: Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467, 1988
30. van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Gate JW: Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174:729, 1991
31. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermueller J, Wilmanns W: Increased serum levels of tumor necrosis factor precede major complications of bone marrow transplantation. Blood 75:1011, 1990
32. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermüller J, Thierfelder S, Behrends U: Involvement of cytokines in graft-versus-host disease and graft-versus-leukemia activity, in Bergmann L, Mitrou PS (eds): Cytokines in Cancer Therapy. Contributions to Oncology 46. Basel, Switzerland, Karger, 1994, p 318